Compare PD & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PD | NVCR |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 636.9M | 1.2B |
| IPO Year | 2019 | 2015 |
| Metric | PD | NVCR |
|---|---|---|
| Price | $6.76 | $17.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $12.63 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 1.9M | 1.7M |
| Earning Date | 05-28-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 416.95 | 21.79 |
| EPS | ★ 1.87 | N/A |
| Revenue | $492,546,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $3.58 | $7.72 |
| Revenue Next Year | $2.88 | $6.74 |
| P/E Ratio | $3.62 | ★ N/A |
| Revenue Growth | 5.36 | ★ 8.28 |
| 52 Week Low | $5.70 | $9.82 |
| 52 Week High | $17.45 | $20.05 |
| Indicator | PD | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 67.38 |
| Support Level | $6.01 | $12.66 |
| Resistance Level | $7.91 | N/A |
| Average True Range (ATR) | 0.38 | 1.01 |
| MACD | -0.03 | 0.23 |
| Stochastic Oscillator | 27.08 | 82.42 |
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.